The estimated Net Worth of Derek M Meisner is at least $751 Thousand dollars as of 17 August 2022. Mr Meisner owns over 8,334 units of X4 Pharmaceuticals stock worth over $100,157 and over the last 6 years he sold XFOR stock worth over $171,405. In addition, he makes $479,464 as Chief Legal Officer & Corp. Sec. at X4 Pharmaceuticals.
Sign up
Mr D XFOR stock SEC Form 4 insiders trading
Mr has made over 8 trades of the X4 Pharmaceuticals stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 8,334 units of XFOR stock worth $5,750 on 17 August 2022.
The largest trade he's ever made was selling 15,909 units of X4 Pharmaceuticals stock on 11 February 2022 worth over $10,977. On average, Mr trades about 4,112 units every 51 days since 2018. As of 17 August 2022 he still owns at least 145,155 units of X4 Pharmaceuticals stock.
You can see the complete history of Mr Meisner stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Derek M. Meisner Esq., J.D. biography
Derek M. Meisner Esq., J.D. is the Chief Legal Officer & Corp. Sec. at X4 Pharmaceuticals.
What is the salary of Mr D?
As the Chief Legal Officer & Corp. Sec. of X4 Pharmaceuticals, the total compensation of Mr D at X4 Pharmaceuticals is $479,464. There are 3 executives at X4 Pharmaceuticals getting paid more, with Paula Ragan having the highest compensation of $2,497,790.
How old is Mr D?
Mr D is 50, he's been the Chief Legal Officer & Corp. Sec. of X4 Pharmaceuticals since . There are 9 older and 4 younger executives at X4 Pharmaceuticals. The oldest executive at X4 Pharmaceuticals, Inc. is Dr. Robert David Arbeit, 73, who is the Sr. VP of Clinical Devel. and Translational Research.
What's Mr D's mailing address?
Derek's mailing address filed with the SEC is 100 Acorn Park Dr 5th floor, Cambridge, MA 02140, USA.
Insiders trading at X4 Pharmaceuticals
Over the last 6 years, insiders at X4 Pharmaceuticals have traded over $2,179,690 worth of X4 Pharmaceuticals stock and bought 25,000 units worth $30,000 . The most active insiders traders include Paula Ragan, Adam S. Mostafa, and Gary Bridger. On average, X4 Pharmaceuticals executives and independent directors trade stock every 19 days with the average trade being worth of $12,232. The most recent stock trade was executed by Mary Di Biase on 9 September 2024, trading 2,642 units of XFOR stock currently worth $1,744.
What does X4 Pharmaceuticals do?
X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, an oral small molecule antagonist of chemokine receptor CXCR4, which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; Phase Ib clinical trial to treat severe congenital neutropenia and Waldenström macroglobulinemia; and Phase IIa clinical trial for the treatment of clear cell renal cell carcinoma. The company is also developing X4P-002 for the treatment of glioblastoma multiforme; and X4P-003 to treat patients suffering from chronic rare diseases. X4 Pharmaceuticals, Inc. has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
What does X4 Pharmaceuticals's logo look like?
Complete history of Mr Meisner stock trades at Genocea Biosciences Inc and X4 Pharmaceuticals
X4 Pharmaceuticals executives and stock owners
X4 Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Paula Ragan,
President, Chief Executive Officer, Corporate Secretary, Director -
Adam Mostafa,
Chief Financial Officer, Treasurer -
Dr. Paula Ragan Ph.D.,
Founder, CEO, Pres, Sec. & Director -
Derek M. Meisner Esq., J.D.,
Chief Legal Officer & Corp. Sec. -
Adam S. Mostafa,
CFO, Treasurer & Assistant Sec. -
Michael Wyzga,
Independent Chairman of the Board -
Gary Bridger,
Independent Director -
Murray Stewart,
Independent Director -
David McGirr,
Independent Director -
William Aliski,
Independent Director -
Rene Russo,
Director -
Candice Ellis,
Director, Corporate Communications & Investor Relations -
Alison Lawton,
Director -
Derek Meisner,
General Counsel -
Arthur Taveras,
Chief Scientific Officer -
Dr. Diego Cadavid M.D.,
Chief Medical Officer -
Carrie Melvin M.B.A.,
Sr. VP of Devel. Operations -
Dr. Robert David Arbeit,
Sr. VP of Clinical Devel. and Translational Research -
Ronny Mosston M.B.A.,
Sr. VP of HR -
Dr. Mary DiBiase Ph.D.,
Chief Operating Officer -
Keith Woods,
Director -
Craecker Francoise De,
Director -
Christophe Arbet Engels,
Chief Medical Officer -
Renato Skerlj,
Chief Scientific Officer -
Lynne E Kelley,
Chief Medical Officer -
Diego Cadavid,
Chief Medical Officer -
Mary Di Biase,
Chief Operating Officer